1,648
Participants
Start Date
July 31, 2008
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2011
Certolizumab pegol (CZP)
400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
Placebo
Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
Birmingham
Montgomery
Phoenix
Tucson
Hot Springs
Little Rock
Fullerton
La Jolla
Los Angeles
Palm Desert
Sacramento
Santa Barbara
Santa Maria
Tustin
Westlake Village
Whittier
Denver
Danbury
Trumbull
Lewes
Newark
Washington D.C.
Boca Raton
Delray Beach
Gainesville
Jacksonville
Orlando
South Miami
Tampa
Tavares
Atlanta
Coeur d'Alene
Idaho Falls
Maywood
Peoria
Rock Island
Springfield
Evansville
Indianapolis
Wichita
Louisville
Covington
Lake Charles
Baltimore
Columbia
Frederick
Wheaton
Boston
Fall River
Battle Creek
Kalamazoo
Lansing
Petoskey
Duluth
Rochester
St Louis
New Brunswick
Voorhees Township
Albany
New York
Orchard Park
Rochester
Roslyn
Smithtown
Syracuse
The Bronx
Asheville
Chapel Hill
Charlotte
Monroe
Wilmington
Columbus
Dayton
Fairfield
Mayfield
Oklahoma City
Erie
Philadelphia
Pittsburgh
West Reading
Wexford
Charleston
Jackson
Amarillo
Austin
Dallas
Fort Worth
Houston
Lubbock
San Antonio
Sugar Land
Salt Lake City
Newport News
Richmond
Spokane
Tacoma
Yakima
Clarksburg
Glendale
Milwaukee
Monroe
Edmonton
Vancouver
Winnipeg
St. John's
Halifax
Hamilton
Kitchener
London
Toronto
Windsor
Montreal
Rimouski
Trois-Rivires
Calgary
Mississauga
Newmarket
Sainte-Foy
Amiens
Cahors
Corbeil-Essonnes
Dreux
Liévin
Montpellier
Mulhouse
Nantes
Orléans
Paris
Pierre-Bénite
Rennes
Saint-Priest-en-Jarez
Bad Neuenahr
Baden
Berlin
Chemnitz
Cologne
Dresden
Duisburg
Erfurt
Erlangen
Freiburg im Breisgau
Friedrichroda
Goslar
Hamburg
Hildesheim
Hoyerswerda
Jena
Kiel
Leipzig
Mainz
München
Neuss
Osnabrück
Rostock
Wiesbaden
Zerbst
Bologna
Genova
Iesi
Modena
Palermo
Pisa
Prato
Siena
Udine
Apeldoorn
Arnhem
Leiden
The Hague
A Coruña
Barcelona
Madrid
Murcia
Oviedo
Pontevedra
Sabadell
Salamanca
San Cristóbal de La Laguna
Santander
Santiago de Compostela
Torrelavega
Lead Sponsor
UCB Pharma
INDUSTRY